Herbal medicines available at RENAME and acquisition by SUS: a contribution to the PNPMF analysis

• Autor(a) principal: Silva, Gabriella Guimarães e
• Data de Publicação: 2022
• Outros Autores: Léda , Paulo Henrique de Oliveira, Oliveira, Danilo Ribeiro de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Fitos
• Texto Completo: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1364
• topic: Herbal drugs; Herbal medicines; Health Unic System; RENAME; ANVISA; Plantas Medicinais; fitoterápicos; Sistema Único de Saúde; RENAME; ANVISA

In 2012, the List of Essential Medicines (RENAME) was published and it includes twelve herbal medicines. The objective of this work is to identify and analyze the supply of herbal medicines by RENAME within the scope of SUS. An exploratory-descriptive study with a quali-quantitative approach was developed with a survey of data through the Health Price Database (BPS) and the website of ANVISA. The results showed: 1- Mikania glomerata (guaco) was the one that most appeared in the BPS as the most purchased herbal medicine by the municipalities (89 records); 2- municipalities in the state of Paraná were the ones that purchased the most herbal medicines (68 records); 3- the purchase modality highlighted was the trading session (93.0%), with a predominance of 95.0% of processed products; 4- 90.9% of companies holding valid registrations are national and concentrated in the South and Southeast; 5- regarding the therapeutic indications, there are no products with the purpose of alleviating anxiety. It is concluded that there are factors that hinder the acquisition of herbal medicines in SUS. However, this study brings important reflections on opportunities, challenges and difficulties in the implementation of herbal medicine in the SUS through RENAME.